Terpestacin is a bicyclo sesterpene produced by Arthrinium and other fungal species first reported in 1993 by Iimura and colleagues at the Bristol Myers Squibb Research Institute, Japan. Terpestacin inhibits syncytium formation induced by HIV infection. Terpestacin inhibits the growth of the phytopathogenic fungi, Alternaria brassicicola, Botrytis cinerea and Fusarium graminearum. Terpestacin inhibits angiogenesis via the ERK pathway and binds with UQCRB subunit of mitochondrial Complex III, resulting in inhibition of hypoxia-induced reactive oxygen species generation.
- Terpestacin, a novel syncytium formation inhibitor, isolated from Arthrinium species. Iimura S. et al. Tetrahedron Lett 1993, 34, 493.
- Fusaproliferin, terpestacin and their derivatives display variable allelopathic activity against some ascomycetous fungi. Cimmino A. et al. Chem Biodiv 2016, 13, 1593.
- Anti-angiogenic activity of terpestacin, a bicyclo sesterterpene from Embellisia chlamydospora. Jung H.J. et al. J Antibiot 2003, 56, 492.